138 related articles for article (PubMed ID: 12052761)
1. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma.
Hsueh EC; Essner R; Foshag LJ; Ye W; Morton DL
Ann Surg Oncol; 2002 Jun; 9(5):486-92. PubMed ID: 12052761
[TBL] [Abstract][Full Text] [Related]
2. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL
J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
4. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
[TBL] [Abstract][Full Text] [Related]
5. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
6. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
7. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
10. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E
Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200
[TBL] [Abstract][Full Text] [Related]
11. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma.
Tsioulias GJ; Gupta RK; Tisman G; Hsueh EC; Essner R; Wanek LA; Morton DL
Ann Surg Oncol; 2001 Apr; 8(3):198-203. PubMed ID: 11314934
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
[TBL] [Abstract][Full Text] [Related]
14. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
16. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.
Bystryn JC; Oratz R; Roses D; Harris M; Henn M; Lew R
Cancer; 1992 Mar; 69(5):1157-64. PubMed ID: 1739915
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
[TBL] [Abstract][Full Text] [Related]
19. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
20. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
